ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer
Open accessThe DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ETS transcription factors regulate important signaling pathways involved in cell differentiation and development in many tissues and have emerged as important players in prostate cancer. However, the biological impact of ETS factors in prostate tumorigenesis is still debated. METHODOLOGY/PRINCIPAL FINDINGS: We performed an analysis of the ETS gene family using microarray data and real-time PCR in normal and tumor tissues along with functional studies in normal and cancer cell lines to understand the impact in prostate tumorigenesis and identify key targets of these transcription factors. We found frequent dysregulation of ETS genes with oncogenic (i.e., ERG and ESE1) and tumor suppressor (i.e., ESE3) properties in prostate tumors compared to normal prostate. Tumor subgroups (i.e., ERG(high), ESE1(high), ESE3(low) and NoETS tumors) were identified on the basis of their ETS expression status and showed distinct transcriptional and biological features. ERG(high) and ESE3(low) tumors had the most robust gene signatures with both distinct and overlapping features. Integrating genomic data with functional studies in multiple cell lines, we demonstrated that ERG and ESE3 controlled in opposite direction transcription of the Polycomb Group protein EZH2, a key gene in development, differentiation, stem cell biology and tumorigenesis. We further demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and through induction of EZH2. CONCLUSIONS/SIGNIFICANCE: These findings provide new insights into the role of the ETS transcriptional network in prostate tumorigenesis and uncover previously unrecognized links between aberrant expression of ETS factors, deregulation of epigenetic effectors and silencing of tumor suppressor genes. The link between aberrant ETS activity and epigenetic gene silencing may be relevant for the clinical management of prostate cancer and design of new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the chromosome rearrangements described above, there is mounting evidence for an oncogenic role for dysregulation of ETS genes in prostate (188, 188a), melanoma (189), and gastrointestinal stromal tumors (140).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Liang, C.-C., Park, A. Y., & Guan, J.-L. (2007) · Nature Protocols · doi:10.1038/nprot.2007.30 · Cited by 4,696 · cited 1×
“Cell migration was assessed using the scratch wound healing assay [47].”
MethodRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 1×
“EZH2 is up-regulated in many cancers, including clinically localized and metastatic prostate cancers [19,37].”
BackgroundPolycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,514 · cited 1×
“EZH2 is a key factor in the execution of development and differentiation programs as well as in maintenance of pluripotency and self-renewal of stem cells [38,39].”
BackgroundInflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621 · cited 3×
“cause of cancer death in western countries [1].”
BackgroundEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundIntegrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922 · cited 2×
“This approach has been applied in previous studies [27,34].”
BackgroundResultDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 1×
“recently attracted significant attention in prostate cancer since the identification of recurrent ETS gene rearrangements leading to their over-expression [2,3,4].”
Background
Cited by
Items 101–142 of 142
Lu, B., Liu, Y., Yao, Y., Yang, T., Zhang, H., Yang, X., Huang, R., Zhou, W., Pan, X., & Cui, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1355551 · Cited by 9
O'Sullivan, Á. G., Eivers, S. B., Mulvaney, E. P., & Kinsella, B. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.005 · Cited by 9
Chromoplexy: A Pathway to Genomic Complexity and Cancer Development
Pellestor, F., Ganne, B., Gaillard, J. B., & Gâtinois, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083826 · Cited by 8
“…a cascade of events (Figure 2), in particular the overexpression of EZH2 , a methyltransferase involved in silencing of tumor suppressor gene [41,47], and the decreased expression of NKX3-1 , an androgen-regulated prostate specific gene which acts as a negative regulator of epithelial cell…”
Angulo, J. C., Lopez, J. I., & Ropero, S. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0231-2 · Cited by 7
“EZH2 overexpression is associated with a high proliferation rate and aggressive neoplasia [99] and correlates with promoter hypermethylation of genes involved in ERG overexpression, epithelialmesenchymal transition and suppression of tumor growth and metastasis [100, 101].”
BackgroundETS1 regulates NKX3.1 5′ promoter activity and expression in prostate cancer cells
Preece, D. M., Harvey, J. M., Bentel, J. M., & Thomas, M. A. (2010) · The Prostate · doi:10.1002/pros.21254 · Cited by 7
“1 promoter by ERG and ESE3 that was mediated via an ETS binding site located between 579 and 573 [48].”
BackgroundBurkhart, D. L., Morel, K. L., Wadosky, K. M., Labbé, D. P., Galbo, P. M., Dalimov, Z., Xu, B., Loda, M. F., & Ellis, L. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0186 · Cited by 8
Linn, D. E., Bronson, R. T., & Li, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120628 · Cited by 7
“1 in prostate cancer cells through induction of the histone methyltransferase EZH2 [15].”
BackgroundDecoding the heterogeneous landscape in the development prostate cancer (Review)
Moreno, Y. Y. S., Sanabria‐Salas, M. C., Varela, R., Mesa, J., & Serrano, M. L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12637 · Cited by 9
Kareddula, A., Medina, D. J., Petrosky, W., Dolfi, S. C., Tereshchenko, I. V., Walton, K., Aviv, H., Sadimin, E. T., Tabakin, A. L., Singer, E. A., et al. (2021) · Therapeutic Advances in Urology · doi:10.1177/17562872211022462 · Cited by 6
Su, Z., Zhang, M., Luo, H., Zhong, J., Tan, J., Xu, Y., Pan, X., Zeng, H., Nie, L., Xu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15694 · Cited by 7
Dubovenko, A., Serebryiskaya, T., Nikolsky, Y., Nikolskaya, T., Perlina, A., JeBailey, L., Bureeva, S. V., Katta, S., Srivastava, S. K., Dobi, A., et al. (2015) · Journal of Cancer · doi:10.7150/jca.8213 · Cited by 6
Buteyn, N. J., LaMantia, S. J., Burke, C. G., Sartori, V. J., Gardner, E., DeBruine, Z. J., Kamarudin, D., Chandler, D. P., Monovich, A. C., Perez, M. W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.14.594150 · Cited by 5
Ma, F., Chen, S., Cecchi, L. G., Ersoy-Fazlioglu, B., Russo, J. W., Arai, S., Awad, S., Calagua, C., Xie, F., Poluben, L., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192368 · Cited by 5
Regulation of EZH2 Expression by INPP4B in Normal Prostate and Primary Prostate Cancer
Zhang, M., Ceyhan, Y., Mei, S., Hirz, T., Sykes, D. B., & Agoulnik, I. U. (2023) · Cancers · doi:10.3390/cancers15225418 · Cited by 4
“1 [54,55], was significantly decreased in the prostates of Inpp4b − / − males [24].”
BackgroundA harmonized resource of integrated prostate cancer clinical, -omic, and signature features
Laajala, T. D., Sreekanth, V., Soupir, A. C., Creed, J. H., Halkola, A. S., Calboli, F. C. F., Singaravelu, K., Orman, M. V., Colin, C., Gerke, T. A., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02335-4 · Cited by 8
Yu, J., Kim, J., & Yang, Y. A. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s35598 · Cited by 4
Zhang, W., Li, T., & Lin, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105559 · Cited by 6
Moreno, Y. Y. S., Sanabria‐Salas, M. C., Mesa, J., Varela‐Ramírez, R., Acosta‐Vega, N. L., & Serrano, M. L. (2022) · Cancer Reports · doi:10.1002/cnr2.1728 · Cited by 2
“It is important to highlight that these subtypes are also found separately, which indicates that the expression of these genes is more complex than the sole reciprocal relationship among them.(6) The SPINK-1 subtype was found in 41% of the samples and 75% of the patients.”
BackgroundYadav, M., Dahiya, M., Chauhan, S., Sharma, S., Rabbani, S. A., Senwar, K. R., Dhillon, A., & Kumar, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100264 · Cited by 2
Laajala, T. D., Sreekanth, V., Soupir, A. C., Creed, J. H., Calboli, F. C. F., Singaravelu, K., Orman, M. V., Colin, C., Gerke, T. A., Fidley, B. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.17.524403 · Cited by 1
“Kunderfranco et al. 75 had the highest number of matching genes with 32 1-to-1 matches and only 2 genes missing.”
ERG (v-ets erythroblastosis virus E26 oncogene like (avian))
Menon, R., Braun, M., & Perner, S. (2012) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/45991 · Cited by 1
Rostad, K. (2011) · NORA - Norwegian Open Research Archives
Novel Research on Fusion Genes and Next-Generation Sequencing
Abbosh, P. H., & Chen, D. Y. T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00004-9
Moreno, Y. Y. S., & Serrano, M. L. (2016) · Acta Biológica Colombiana · doi:10.15446/abc.v21n3.50477
Olkhov‐Mitsel, E. (2015) · TSpace (University of Toronto)
Investigation of Novel Progression-related Methylation Events and HOXD Genes in Prostate Cancer
Kron, K. J. (2012) · TSpace (University of Toronto)
Targeting of Epigenetic Modifier EZH2 in Oropharyngeal Squamous Cell Carcinomas
Lindsay, C. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3cn6zf0h
Pharmacoepigenetics of EZH2 Inhibitors
Lindsay, C., Kostiuk, M. A., & Biron, V. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00009-7
Exploring Urinary Epigenetic Biomarkers for Identification of Aggressive Prostate Cancer
Zhao, F. (2020) · TSpace (University of Toronto)
Role of Epigenetic alterations in the development of cancers
Mehboob, R. (2022) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v5i2.346
Role of Epigenetic alterations in the development of cancers
Mehboob, R. (2021) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v2i02.20
Ricci, F., Bizzaro, F., Cesca, M., Guffanti, F., Ganzinelli, M., Decio, A., Ghilardi, C., Perego, P., Fruscio, R., Buda, A. A., et al. (2023) · doi:10.1158/0008-5472.22403516
Self-citationRicci, F., Bizzaro, F., Cesca, M., Guffanti, F., Ganzinelli, M., Decio, A., Ghilardi, C., Perego, P., Fruscio, R., Buda, A. A., et al. (2023) · doi:10.1158/0008-5472.22403516.v1
Self-citationAlbino, D., Longoni, N., Curti, L., Grand, M. M., Pinton, S., Civenni, G., Thalmann, G. N., D’Ambrosio, G., Sarti, M., Sessa, F., et al. (2023) · doi:10.1158/0008-5472.22393653.v1
Self-citationAlbino, D., Longoni, N., Curti, L., Grand, M. M., Pinton, S., Civenni, G., Thalmann, G. N., D’Ambrosio, G., Sarti, M., Sessa, F., et al. (2023) · doi:10.1158/0008-5472.22393641
Self-citationAlbino, D., Longoni, N., Curti, L., Grand, M. M., Pinton, S., Civenni, G., Thalmann, G. N., D’Ambrosio, G., Sarti, M., Sessa, F., et al. (2023) · doi:10.1158/0008-5472.22393653
Self-citationData from EZH2: Not EZHY (Easy) to Deal
Deb, G., Singh, A. K., & Gupta, S. (2023) · doi:10.1158/1541-7786.c.6539991.v1
Pellestor, F., Gaillard, J. B., Ganne, B., & Gâtinois, V. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4750-9_3
Albino, D., Sandrini, G., Musumeci, C., Storelli, E., Papa, G., Impellizzieri, D., Cacciatore, A., Cassanmagnago, G. A., Balla, A., Mosole, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690649
Self-citationEtude du rôle des protéines Polycomb Pcgf1 et Ezh2 chez le poisson zèbre Danio rerio
Dupret, B. (2017) · theses.fr (ABES) · doi:10.70675/8f5fe7e1z5229z4a9eza0a5z877106bbd1be
Metadata
- Authors
- Kunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M.
- Affiliations
- Istituto Oncologico della Svizzera Italiana (CH)
- Fondazione Edo ed Elvo Tempia (IT)
- Corresponding author
- Carbone, Giuseppina M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-05-10
- Volume
- 5
- Issue
- 5
- Pages
- e10547
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2866657
- OpenAlex
- W1982538300
- Cited by
- 143
- References
- 49
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 7 · 2014: 8 · 2013: 19 · 2012: 16
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Uni Genf
- Funders
- National Science Foundation
- Compagnia di San Paolo
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A, 118113)
- Oncosuisse
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ETS transcription factors, prostate cancer, EZH2, NKX3.1, epigenetic silencing, ERG, Polycomb group proteins, tumor suppressor, prostate tumorigenesis, transcriptional regulation, tumor subtypes, gene expression signatures
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Transcriptional Regulator ERG, Aged, Cell Movement, DNA-Binding Proteins, Histones, Humans, Lysine, Male, Methylation, Middle Aged, Models, Genetic, Prostatic Neoplasms, Transcription Factors, Transcription, Genetic, Trans-Activators, Up-Regulation, Gene Expression Regulation, Neoplastic, Homeodomain Proteins, Gene Silencing, Gene Expression Profiling, Anoikis, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-ets, Gene Knockdown Techniques, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.